Login / Signup

ALK+ histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition.

Paul Geraeds KempsJennifer L PicarsicBenjamin H DurhamZofia Hélias-RodzewiczLaura Sophia Hiemcke-JiwaCor van den BosMarianne D van de WeteringCarel J M van NoeselJan A M van LaarRobert M VerdijkUta E FluckePancras C W HogendoornF J S H Sherida Woei-A-JinRaf M E SciotAndreas BeilkenFriedrich FeuerhakeMartin EbingerRobert MöhleFalko FendAntje BornemannVerena WiegeringKaren ErnestusTina MéryOlga Gryniewicz-KwiatkowskaBozenna Dembowska-BaginskaDmitry A EvseevVsevolod PotapenkoVadim V BaykovStefania GaspariSabrina RossiMarco GessiGianpiero TamburriniSébastien HéritierJean DonadieuJacinthe Bonneau-LagacherieClaire LamaisonLaure FarnaultSylvie FraitagMarie-Laure JullieJulien HarocheMatthew CollinJackie AlloteyMajid MadniKerry TurnerSusan PictonPasquale M BarbaroAlysa PoulinIngrid S TamDina El DemellawyBrianna EmpringhamJames A WhitlockAditya RaghunathanAmy A SwansonMariko SuchiJon M BrandtNabeel R YaseenJoanna L WeinsteinIrem EldemBryan A SiskVaish SridharMandy M AtkinsonLucas R MassothJason L HornickSanda AlexandrescuKee Kiat YeoKseniya Petrova-DrusStephen Z PeekeLaura Munoz-ArcosDaniel G LeinoDavid Douglas GrierRobert LorsbachSomak RoyAshish R KumarShipra GargNishant TiwariKristian T SchafernakMichael M HenryAstrid G S van HalterenOussama AblaEli L DiamondJean François Emile
Published in: Blood (2021)
ALK-related histiocytosis (formerly ALK-positive histiocytosis) is a rare subtype of histiocytic neoplasm first described in 2008 in three infants with multisystemic disease involving the liver and hematopoietic system. This entity has subsequently been documented in case reports and series to occupy a wider clinicopathologic spectrum with recurrent KIF5B-ALK fusions. The full clinicopathologic and molecular spectra of ALK-related histiocytosis remain, however, poorly characterized. Here, we describe the largest study of ALK-related histiocytosis to date, with detailed clinicopathologic data of 39 cases, including 37 cases with confirmed ALK rearrangements. The clinical spectrum comprised distinct clinical phenotypic groups: infants with multisystemic disease with liver and hematopoietic involvement, as originally described (Group 1A: 6/39), other patients with multisystemic disease (Group 1B: 10/39), and patients with single-system disease (Group 2: 23/39). Nineteen patients of the entire cohort (49%) had neurologic involvement (seven and twelve from Groups 1B and 2, respectively). Histology included classic xanthogranuloma features in almost one third of cases, whereas the majority displayed a more densely cellular, monomorphic appearance without lipidized histiocytes but sometimes more spindled or epithelioid morphology. Neoplastic histiocytes were positive for macrophage markers and ALK, and often conferred strong expression of phosphorylated-ERK, confirming MAPK pathway activation. KIF5B-ALK fusions were detected in 27 patients, while CLTC-ALK, TPM3-ALK, TFG-ALK, EML4-ALK and DCTN1-ALK fusions were identified in single cases. Robust and durable responses were observed in 11/11 patients treated with ALK inhibition, ten with neurologic involvement. This study presents the existing clinicopathologic and molecular landscape of ALK-related histiocytosis, and provides guidance for the clinical management of this emerging histiocytic entity.
Keyphrases